Price
Frequently asked questions
What is Argenx's market capitalization?
What is the Earnings Per Share (EPS) for Argenx?
What are the analyst ratings and target price for Argenx's stock?
What is Argenx's revenue over the trailing twelve months?
What is the EBITDA for Argenx?
What is the 5-year beta of Argenx's stock?
How many employees does Argenx have, and what sector and industry does it belong to?
What is the free float of Argenx's shares?
Financials
Market Cap
$35.77B5Y beta
0.56EPS (TTM)
-$0.836Free Float
60.30MRevenue (TTM)
$1.85BEBITDA (TTM)
-$254.94MPricing
Analyst Ratings
The price target is $539.02 and the stock is covered by 20 analysts.
Buy
17
Hold
2
Sell
1
Information
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
1,148
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker